<DOC>
	<DOCNO>NCT01959529</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial compare cardiovascular safety insulin degludec versus insulin glargine subject type 2 diabetes high risk cardiovascular event .</brief_summary>
	<brief_title>A Trial Comparing Cardiovascular Safety Insulin Degludec Versus Insulin Glargine Subjects With Type 2 Diabetes High Risk Cardiovascular Events</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 diabetes Age equal 50 year predefined previous cardiovascular disease ( ) renal disease age equal 60 year predefined cardiovascular risk factor HbA1c ( glycosylated haemoglobin ) equal 7.0 % HbA1c 7.0 % current insulin treatment correspond equal 20 U basal insulin per day One oral injectable antidiabetic agent ( ) An acute coronary cerebrovascular event previous 60 day Planned coronary , carotid peripheral artery revascularisation Chronic heart failure NYHA ( New York Heart Association ) class IV Current past ( within last 5 year ) malignant neoplasm ( except basal cell squamous cell skin carcinoma )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>